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Abstract: According to the latest available data, cancer is the second leading cause of death,
highlighting the need for novel cancer therapeutic approaches. In this context, immunotherapy is
emerging as a reliable first-line treatment for many cancers, particularly metastatic melanoma. Indeed,
cancer immunotherapy has attracted great interest following the recent clinical approval of antibodies
targeting immune checkpoint molecules, such as PD-1, PD-L1, and CTLA-4, that release the brakes
of the immune system, thus reviving a field otherwise poorly explored. Cancer immunotherapy
mainly relies on the generation and stimulation of cytotoxic CD8 T lymphocytes (CTLs) within the
tumor microenvironment (TME), priming T cells and establishing efficient and durable anti-tumor
immunity. Therefore, there is a clear need to define and identify immunogenic T cell epitopes to use in
therapeutic cancer vaccines. Naturally presented antigens in the human leucocyte antigen-1 (HLA-I)
complex on the tumor surface are the main protagonists in evocating a specific anti-tumor CD8+ T
cell response. However, the methodologies for their identification have been a major bottleneck
for their reliable characterization. Consequently, the field of antigen discovery has yet to improve.
The current review is intended to define what are today known as tumor antigens, with a main focus
on CTL antigenic peptides. We also review the techniques developed and employed to date for
antigen discovery, exploring both the direct elution of HLA-I peptides and the in silico prediction
of epitopes. Finally, the last part of the review analyses the future challenges and direction of the
antigen discovery field.
Keywords: tumor antigens; immunopeptidome; cancer immunotherapy; epitope prediction
1. Introduction
The recent clinical success of antibodies targeting immune checkpoint molecules, such as
programmed death receptor-1 (PD-1), its ligand PD-L1, and cytotoxic T cell-associated antigen 4
(CTL-A4), have led to a new and strong interest in the field of cancer immunotherapy [1,2]. Immune
checkpoint inhibitors (ICIs) release the brakes of the immune system, reviving and boosting the
effector function of specific anti-tumor T cells [3]. In 2018, James Patrick Allison and Tasuku Honjo
received the Nobel prize for medicine “for their discovery of cancer therapy by inhibition of negative
immune regulation” [4,5]. The overall response to ICIs is reportedly unsatisfactory for many types of
cancer [6], highlighting the need to combine ICIs with cancer immunotherapeutic approaches, such as
therapeutic cancer vaccines, with the artificial generation, stimulation, and tumor microenvironment
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(TME) infiltration of cancer-specific CD8+ T cells called cytotoxic T lymphocytes (CTLs) [2,7–9].
CTLs patrol the whole organism, checking the major histocompatibility complex (MHC), called the
human leucocytes antigen (HLA) in humans, that possesses an antigenic peptide that is typically
8–11 aminoacidic residues in length and expressed on the cellular surface. If an aberrant peptide is
eventually spotted in the HLA-I complex, the CTLs kill the cell.
In this context, to create effective tumor protection and rejection strategies, the reliable identification
of tumor antigens in the HLA-I complex plays a pivotal role. To date, the methodologies for the correct
identification of antigens in the HLA-I complex rely on the direct isolation of peptides from the HLA-I
complex and/or the in silico prediction of relevant antigens [10,11].
The direct identification of peptides from the HLA complex is accomplished using different
techniques, of which immunoaffinity purification (HLA immunoprecipitation) and the extraction
of HLA peptides are the most well-established [12]. Isolated peptides are identified by tandem
mass-spectrometry (MS/MS). The entire process is highly laborious and time-consuming [13,14]. It has
been reported that immunoaffinity purification produces a low yield (i.e., 1–3%) [15], even though
additional experiments in different settings are needed to better determine how much of the sample
is lost [16]. The peptide isolation procedure is universally recognized as the bottleneck of the entire
procedure and therefore requires improvement [16].
In the antigen discovery process, in silico tools are used to predict immunologically relevant
antigens. The identification of target candidates relies on bioinformatic approaches that allow a
structural analysis of genomic and proteomic data. For instance, next generation sequencing (NGS)
approaches can benefit from the use of epitope prediction tools to combine two kinds of information:
the differential gene expression in cancer compared to matched healthy tissue and the probability
of those candidates to be presented on the cell surface onto the HLA molecule [17,18]. To achieve
this, the actual bioinformatic tools contain T cell epitope algorithms that are able to predict putative T
cell epitopes based on the well-characterized rules to which HLA-I presented peptides adhere [19,20].
Indeed, several predictors of HLA binders have been developed [21]; these will be defined in Section 4.
HLA binding is only one part of the story; today, the entire processing machinery can be taken into
account (e.g., proteasomal cleavage, transporter-associated antigen processing (TAP) transport) by the
bioinformatic algorithms to predict relevant T cell epitopes [21].
NGS and in silico tools are effective methods in antigen discovery; however, improvements are
needed. These methods lack rich and experimentally validated datasets, thus decreasing the accuracy
of the predictive algorithms. The bioinformatic predictions give hints, but the selection of relevant
epitopes from among the candidates always requires experimental validation [18,21].
This paper presents the information necessary to understand the antigen discovery field.
It describes the concept of antigens, focusing mainly on CTL antigenic peptides. It then provides a
concise analysis of the methods endorsed for the antigen discovery process, including in vitro and in
silico approaches. It also highlights the gaps and challenges in the field.
2. Antigens
The word “antigen” refers to the molecular structure seen by the antibodies or to any molecule or
linear molecular fragment derived from the processing of the native antigen that can be recognized by
T cell receptors (TCRs) [22]. This paper mainly examines CD8+ T cell-restricted antigens. The existence
and role of tumor antigens have been discussed since 1940 and were reported on before the discovery
of T cells, which occurred in the 1960s [23,24]. In 1943, Gross et al. performed a pivotal experiment
that showed for the first time the role of the immune system in tumor rejection [25]. Briefly, mice were
treated with methylcholanthrene and subsequently developed tumors. The tumors were then resected,
and the tumor cells were implanted back into the mice. The mice then rejected the second tumor.
This experiment demonstrated that acquired immunity was induced and directed against the tumor
and that the rejection did not depend upon genetic differences between the inoculated mice and the
mice that produced the tumor cells [25].
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Later, Boon and colleagues achieved similar results using mutagen-treated murine cell lines
that failed to form tumors in syngeneic mice; this research confirmed that tumors express antigens
recognized by CTLs and confirmed the role of the immune system in rejecting malignant cells [26,27].
However, the molecular nature of the antigens expressed by tumors and recognized by CTLs was only
discovered in 1989 by Lurquin et al. [28]. The researchers identified a single peptide recognized by CTLs
that differed from the self-protein by single point mutation. This observation clearly showed that upon
mutation, the tumors expressed altered proteins, thus labeling the cells for CTL recognition [28,29].
Today, based on the expression of the parental gene, tumor antigens can be classified into the
general categories of tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) [30]
(Figure 1).
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trials [40–42]. The genes belonging to the apoptosis pathway are also upregulated in tumor cells
compared to healthy tissues, representing a source of T cell epitopes. For instance, a peptide derived
from survivin, an apoptosis inhibitor protein, was used to generate CTLs in vitro from healthy donors;
matched cell lines and primary malignant cells from patients were then lysed by those T cells [43].
In addition, a p53 derived wild type peptide (L9V) was used to generate in vitro CTLs that were able
to kill squamous carcinoma cell lines in an L9V-HLA-dependent fashion [44].
As TAAs have a higher expression level in tumors compared to normal tissue and are shared
among several tumors, a safe use for them has been proposed for cancer therapeutic approaches.
For instance, novel chimeric antigen receptor (CAR) T cells have largely been adopted to target this
class of antigens [31]. CAR T cells consist of an extracellular domain made of the variable region
of the antibody’s heavy and light chains linked to the intracellular signaling domain (CD3-zeta,
CD28, 41BB). This characteristic makes the CAR T cells able to kill the target in an HLA-independent
manner [45]. The adoption of anti-CD19 CARs has showed good clinical outcomes in the treatment of
B cell lymphomas and leukemias [46–48].
However, the main drawback in using TAAs in cancer immunotherapy is the feasibility of the
expression analysis of these proteins in every single tissue under every physiological condition;
this hinders a comprehensive safety profile of the TAAs [31]. Indeed, potential hazards (i.e., “on-target,
off-tumor” toxicity, onset of autoimmune disease) associated with the clinical treatment based on these
molecules have been reported. For instance, CAR T cells targeting carbonic anhydrase IX (CAIX) in RCC
patients induced liver toxicity, requiring cessation of the treatment. Biopsies revealed CAIX expression
in the bile duct epithelium with T cell infiltration, including CAR T cells; this is a typical example
of “on-target, off-tumor” toxicity [49]. Moreover, the central and peripheral tolerance mechanisms
eliminate the T and B cells’ ability to recognize self-antigens. A TAA peptide-based vaccine must break
the tolerance, thus stimulating the low-affinity and rare T cells still circulating. This could interfere
with the development of a proper cancer therapeutic vaccine [30,50]. The identification and use of an
effective vaccine adjuvant could overcome the problem, delivering benefits to cancer patients [51].
The differentiation antigens represent normal proteins which are expressed as a consequence
of a specific function of the target tissue. These were first reported in melanoma in which proteins
(e.g., tyrosinase, Melan-A/MART-1, gp100/Pmel17) involved in melanin production or melanosome
generation were often observed to be targets for CTLs from melanoma patients and healthy donors [35,52,53].
In the 1993 work of Brichard et al., lymphocytes derived from two melanoma patients were stimulated
with irradiated cells from the autologous melanoma, and CTLs that were able to lyse them were
obtained. The authors then demonstrated that the lysis was antigen HLA-0201-specific, and upon using
the cloning approach, they identified the gene encoding the antigen as tyrosinase [53]. Rosenberg and
colleagues administered tumor-infiltrating lymphocytes (TILs) to treat metastatic melanoma patients
and had good results. The authors used the TILs to clone and determine the antigens involved in the
anti-tumor response. In 1994, Rosenberg and colleagues established a CTL cell line called TIL1200 from
a metastatic melanoma patient and were able to lyse the autologous melanoma and other melanoma
HLA-0201+ cell lines. The authors showed that TIL1200 recognized a self-antigen not mutated in the
HLA-0201 context and that the antigen sequence belonged to a membrane glycoprotein known as
gp100/Pmel17 [54]. In the same year, Rosenberg and colleagues identified a shared and commonly
expressed HLA-0201-restricted melanoma antigen that was recognized by T cells 1 (MART-1), applying a
similar approach to that used to isolate gp100/Pmel17 [55]. In the following years, other melanoma
differentiation antigens were identified, such as TRP1/gp75 and TRP2 (tyrosinase-related proteins),
in the context of the HLA-A31 molecule [56,57]. Later, the TRP2 case was reviewed to identify
an HLA-0201-restricted peptide, as HLA-0201 occurs frequently in the population. Based on the
peptide-binding motif for HLA-A0201 and experimental validation, TRP2 peptides 180–188 were
reported, and the sequence was found to be identical to the one recognized by H2Kb-restricted B16
murine melanoma CTLs, paving the way for a murine tumor immunotherapy model [58]. Furthermore,
differentiation antigens such as prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA)
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are used for prostate cancer immunotherapy. Naturally expressed HLA-02 restricted peptides from
PAP were identified through sequence analysis and in vitro validation [59]. Moreover, two PSA
HLA-02-restricted peptides which are capable of eliciting CTL responses have been reported by
Correale et al. [60]. In addition, immunization experiments using HLA-0201 transgenic mice were
employed to identify a peptide from carcinoembryonic antigens (CEA) [61]. This is a glycoprotein
overexpressed in colon rectal cancer and other selected epithelial cancers, while in normal conditions,
its expression is restricted to fetal development and in adults’ tissue in the epithelial cells of the
gastrointestinal tract [62,63].
The main disadvantage in exploiting differentiation antigens as vaccines for cancer therapy is the
onset of autoimmune toxicity. In cases of targeting melanoma-melanocyte antigens, reactions such as
severe skin rashes and vitiligo lesions have been reported [64,65]. CAR T cells targeting CEA that were
used to treat three patients with metastatic colorectal cancer showed a promising outcome in at least
one patient; however, severe transient colitis was induced, most probably due to the CEA presence
in the colonic mucosa [62]. These observations highlight the importance of targeting tumor-specific
antigens and/or antigens with limited expression in normal tissues (e.g., cancer germline/cancer testis
antigens).
Cancer germline/cancer testis antigens (CTAs) are a large family (the CT database consists of 204
genes [66]) of tumor-associated antigens expressed in human tumors of different histological origins
but not in normal tissue, except for testis and placenta tissue [67]. In 1991, Van der Bruggen and
co-workers identified the first human gene that encoded for a cancer testis antigen [68]. The authors
isolated the CTLs that were capable of lysing the autologous cell line derived from the melanoma
patient MZ2. Using a clonal sub-line and a DNA cloning approach, they identified the gene which
was able to sensitize the sub-line to the CTL lysis. This gene was named melanoma antigen family A,
1 (MAGEA1), and it is expressed in many human tumors of different histological types. No expression
was detected in normal tissues, with the exception of testis and placenta tissue [68,69]. In the same
work, another two MAGE members were reported, MAGE A2 and MAGE A3 [68]. Subsequently,
the nonapeptides derived from HLA-A1-restricted MAGE A1 and MAGE A3 were described [70,71].
After this, many antigens were identified in diverse tumors with restricted expression in testis
tissue; Old and Chen called these cancer testis (CT) antigens [72]. To date, the MAGE family
is subdivided into type I and type II. Type I comprises three sub-families, MAGE-A, -B, and -C,
and contains the relevant CTAs. Type II includes the MAGE-D, -E, -F, -G, -H, and -L sub-families and
Necdin that are expressed in different adult tissues [73–75]. Several members have been identified
in the MAGE group [76], and MAGE A3 is one of the most frequently expressed TAAs in many
tumors, including melanoma, non-small cell lung carcinoma (NSCLC), and head and neck tumors [77].
In melanoma, the preferentially expressed antigen of melanoma (PRAME) is another example of a
CTA; PRAME is defined as a testis-selective rather than a testis-restricted CTA as its expression has
been observed in endometrial, ovarian, and adrenal gland tissues in addition to testis tissue [78].
Building on the work by Ikeda and co-workers [79], Kessler et al. subsequently identified four HLA-0201
peptides that were restricted in PRAME [80]. In 2011, Quintarelli and colleagues were able to generate
PRAME-specific CTLs from both healthy donors and leukemia patients [81]. In 1997, the serological
analysis of recombinant tumor cDNA expression libraries (SEREX) technique was used by Chen et al.
to identify novel tumor antigens in esophageal squamous cell carcinoma patients; the screening revealed
sequences belonging to eight genes, among them New York esophageal squamous cell carcinoma 1
(NY-ESO 1), that were expressed in normal tissue, such as testis and ovarian tissue, and in several tumors,
such as melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma [82].
Since then, NY-ESO1 has been employed in several immunotherapy-based treatments [83]. For instance,
recombinant NY-ESO1 protein was used in combination with the adjuvant ISCOMATRIX in 46 patients
with resected NY-ESO1+ tumors. Overlapping peptides were then employed to verify the T cells’
response to NY-ESO1 upon vaccination, showing CD4+ and CD8+ T cells’ specific response to both
known and uncharacterized peptides derived from NY-ESO1 [84]. In 1997, Türeci et al. used the
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SEREX technique to investigate human melanoma and described a novel CTA gene called synovial
sarcoma X chromosome breakpoint (SSX2) [85], to which a T cell response has been reported in
patients with tumors of diverse histological origins [86]. An analysis of the sub-clones derived
from the MZ2 melanoma patient allowed the identification of the B melanoma antigen (BAGE) gene
and the HLA-Cw1601-restricted peptide [87]; BAGE expression was found only in testis and tumor
(e.g., bladder cancer) tissues, and thus was found to be a member of the CTA family. Using a
similar experimental procedure, other CTAs were identified—the gene G antigen 1 (GAGE) and the
HLACw0601-restricted peptide [88].
Being immunologically privileged sites, the testes and placenta do not express HLA molecules [89];
therefore, CTAs are promising targets for cancer immunotherapy. Indeed, MAGE A3 as a recombinant
protein has been used in the largest ever phase III lung cancer clinical trial, the MAGE A3 as Adjuvant
Non-Small Cell Lung Cancer Immunotherapy (MAGRIT) trial [90]. In phase II, the vaccination protocol
was well tolerated and the results promising; however, MAGRIT failed to show any improvement in
disease-free survival (DFS) when compared with a placebo [91]. In addition, TCR gene modified T
cells to target the MAGEA3/A12 HLA-A0201 restricted peptide were used to treat nine patients with
tumors expressing MAGE A3/A12 in a phase I/II clinical trial. The encouraging cancer regression
that was observed was dampened by severe neurotoxicity that resulted in the deaths of two patients.
Subsequent analysis revealed the expression of MAGE A12 in the brain, explaining the inflammation
and neuronal degeneration that was observed [92]. The use of CTAs, such as MAGE family members,
is promising; however, caution is required in further applications.
2.2. Tumor-Specific Antigens
TSAs are a category of antigens restricted to tumors and are not found in healthy cells; this is the
result of malignant mutations or the expression of viral elements. Neoantigens, oncoviral antigens,
and endogenous retroviral elements belong to this category [30,35,93].
Neoantigens are a subset of TSAs produced as a direct consequence of genetic alteration caused by
tumor DNA mutations (e.g., non-synonymous single point mutations, frameshifts, insertions/deletions)
and are patient-specific [94,95]. In 1995, Coulin et al. reported the first example of a neoantigen [96].
The authors identified the source gene of the antigen that was recognized by an autologous CTL and
called it melanoma ubiquitous mutated (MUM-1). As the gene was expressed ubiquitously, the authors
wondered whether a mutation had occurred in the gene to induce an anti-tumor T cell response.
Actually, MUM-1 in the melanoma cells carried a single point mutation that resulted in an amino
acid change in the nonapeptide HLA-B44 restricted, making it suitable for interaction with the T
cells [96]. Several other neoantigens have since been identified. For instance, Rosenberg and colleagues
discovered a single point mutation in the β catenin sequence in one melanoma patient that resulted in
a change from a serine to a phenylalanine residue at position 37; the derived peptide (SYLDSGIHF)
showed a high affinity binding for HLA-A24, the patient’s HLA allele [97]. Moreover, a single point
mutation in the gene encoding CDK4 resulted in the generation of an HLA-A0201-restricted peptide
that was recognized by autologous CTLs in the melanoma patient, and the mutation altered the cell
cycle regulation [98]. A mutation in the CASP-8 gene that reduced the function of the protein and
generated an HLA-B3503-restricted peptide that was recognized by autologous CTLs was reported in
a patient with squamous cell carcinoma of the oral cavity [99].
The neoantigens in cancer immunotherapy have the undiscussed advantage of being non
self-antigens and hence the T cells are not affected by central tolerance, making them highly
immunogenic antigens [94]. However, their main limitation is their great variability within and
between tumors. Great variability within tumors can induce negative selection, allowing the survival
of the cancer cells that no longer express the neoantigens. Great variability between tumors requires
characterization and the development of a specific vaccine for each patient. In addition, the mutational
burden plays a pivotal role in the generation of neoepitopes. Tumors with a high mutation frequency
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are most likely to generate neoantigens. Tumors with a low mutation burden may be difficult to
investigate in terms of identifying neoantigens and subsequent vaccine production [31,35].
Oncoviral antigens consist of proteins derived from the viruses driving the oncogenic
transformation; these proteins are the source of peptides present on the cellular surface in the
HLA context and recognized by T cells. As oncogenic viruses are shared by the same kinds of tumors,
this class of antigen is not patient-specific [30,35]. Prophylactic vaccines have been produced and mainly
rely on eliciting neutralizing antibodies to prevent the virus from entering the cells. The treatment
of established tumors involves targeting T cell epitopes [30]. For instance, human papillomavirus
(HPV) is associated with benign papilloma or warts and cancer of the cervix, anus, penis, and head and
neck [100]. Ramos et al. isolated PBMCs from patients with HPV+ cancer and stimulated them in vitro
with a mix of HLA-I-restricted and HLA-II restricted peptides, covering the E6/E7 proteins of HPV16;
the authors were able to demonstrate that the patients had E6- and E7-specific T cells [101]. These have
been called HPV-ST, and an on-going phase I clinical trial is evaluating the effect of HPV-ST cells in
treating HPV+ tumors (NCT02379520). Another example is the development of therapeutic vaccines
for cancers related to the Epstein–Barr virus (EBV) which is involved in the onset of several disorders,
such as B-cell lymphoproliferative disorders and nasopharyngeal carcinoma [102,103]. In a phase I
clinical trial, 16 patients with established HBV+ tumors were treated with modified vaccinia Ankara
(MVA) encoding the full length of LMP2 and the C-terminal of EBNA1 proteins from EBV. A specific T
cell response to LMP2 and/or EBNA1 was detected, showing the feasibility of boosting an EBV-specific
immune response [104]. However, the extent of the clinical benefits is still being investigated in a phase
II clinical trial (NCT01094405). Oncoviral antigens lack expression in healthy cells, making them highly
tumor-specific. They are also common to patients. However, 15% of cancers have a viral etiopathology,
limiting their clinical application [105,106].
Endogenous retroviral elements (ERVs) or human endogenous retroviral elements (HERVs) are
fragments of genomic DNA derived from the integration of retrotranscribed retroviral RNAs that
infected the germ line cells of humans’ ancestors. Over time, ERVs have been vertically transmitted and,
to date, they represent 8% of the human genome. ERVs have accumulated mutations over time, losing the
capability of producing competent replicative viral particles [107]. Moreover, epigenetic mechanisms
(e.g., methylation) suppress most of their expression in healthy cells. For instance, in the thymus,
ERVs are partially epigenetically silenced, and ERVs which are reactive to T cells do not go through
complete negative selection [108]. In cancer, ERVs are induced upon malignant transformation and/or
epigenetic therapy, becoming targets for cancer therapeutic approaches [109]. In 2015, Rooney at al.
investigated the cytolytic activity and expression pattern associated with 66 ERVs in tumors compared
to healthy tissues. Surprisingly, they found three ERVs (ERVH5, ERVH48-1, and ERVE4) with minimal
or undetectable expression in normal tissue and overexpression in tumors; these have been termed
tumor-specific endogenous retroviruses (TSERVs) [93]. Interestingly, in regard to ERVE4, Rooney´s
data had already been experimentally validated. For instance, following hematopoietic stem cell
transplantation (HSCT), RCC patients experienced disease regression. Child and colleagues found
RCC-reactive CD8+T cells derived from the donor. Using a cDNA cloning approach, the authors
identified the antigen in HERV-E gene products and described an HLA-A11-restricted 10-mer peptide
(ATFLGSLTWK) as the target recognized by the tumor-reactive CTLs [110]. The same authors also
reported the identification of three HLA-A0201-restricted peptides derived from HERV4env that were
able to elicit RCC-reactive CTL responses [111]. ERVH-5 has been reported in bladder, colorectal,
head and neck, lung squamous, ovarian, stomach, and uterine cancers. ERVH48-1 is prominently
expressed in bladder cancer and prostate cancer [109]. Schiavetti et al. described CTLs which were
reactive against the peptide derived from HERV-K-MEL in two melanoma patients. The authors
determined that the peptide sequence (MLAVISCAV) was HLA-A2-restricted, showing that the CTLs’
reactivity against the peptide occurred only in the two patients and not in the healthy donors [112].
Based on the presence of HERV-K gag proteins in the cytoplasm of primary tumor cells and on the
detection of antibodies to HERV-K gag in patients with seminoma, Rakoff–Nahoum investigated
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the HERV-K-specific T cell-mediated immune response in the blood of those patients. The authors
synthetized 15 HERV-K predicted peptides based on the HLA-I binding motif and proline-enriched
region. Next, PBMCs from seminoma patients and healthy donors were screened with four pools of
these peptides. The T cell reactivity was higher in at least three pools of peptides in the seminoma
patients compared to the healthy donors [113].
Their high tumor specificity and expression [93] and incomplete T cell tolerance [108] make ERVs
the ideal target for cancer immunotherapeutic approaches. In addition, autologous CTLs which are
able to recognize HLA-restricted peptides have been reported [110–113], and ERVs are common to
cancer patients. This allows for off-the-shelf therapy. However, the epitopes recognized by CTLs
which are found in cancer patients are still few, and the expression of different HERV families in
cancer is still limited. Therefore, future proteomic analysis, especially of the thymus, and an in-depth
understanding of the mechanisms involved in HLA-I presentation will shed light on the use of ERVs
in cancer immunotherapy [109].
3. In Vitro Methods for HLA Ligand Enrichment
3.1. Immunopeptidome
The existence and role of tumor antigens in eliciting a specific anti-cancer immune response,
combined with the discovery of CD8+ T cell sub-populations which are able to recognize and kill
tumor cells in an HLA I antigen- restricted manner, make the identification of epitopes recognized
by CD8+ T cells a priority in the cancer therapeutic field. The peptides which are bound to the
HLA complex and found on the cellular surface are referred as immunopeptidomes or ligandomes.
The methods developed to study and analyze these are known as immunopeptidomics. The aim
of immunopeptidomics is to reliably identify immunopeptidomes and thus guide the development
of cancer therapeutic vaccines. The direct isolation of HLA peptides from the cell surfaces can be
accomplished using different techniques. In this section, we describe the past and present approaches
to the direct isolation of peptides in order to investigate the immunopeptidome landscape, highlighting
the advantages and disadvantages of each (Figure 2).
3.1.1. Acid Stripping
In 1993, Storkus et al. published for the first time a method for the direct isolation of peptides
from the HLA-I complex based on acid stripping. The method consisted of treating the cells with a
citrate–phosphate buffer at pH 3.3 for a period as short as 15 s, thus allowing the cells to remain viable
and become phenotypically class I-deficient [114]. After the treatment, a flow cytometry analysis of
the acid-treated cells revealed the retention of class I heavy chains of the HLA complex in the cell
membrane, while the class I light chain (β-2 microglobulin) was absent. Since β-2 microglobulin is
essential to stabilize the binding of the peptide within the complex, its dissociation is directly associated
with the release of HLA-bound peptides. Storkus et al. collected the supernatant from acid-treated,
influenza A strain-infected cells and separated the fractions using reverse-phase high performance
liquid chromatography (RP-HPLC). Next, the fractions were analyzed for their capacity to sensitize a B
cell line to lysis which was mediated by a CTL line that was specific to the influenza A matrix peptide
(Flu M1 57-68). Thus, the fractions that were able to induce the lysis were identified. The fractions
contained a peptide with a sequence similar to the Flu M1 58-66 sequence [114].
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Following this work, the same authors used the aforementioned method to extract peptides
from human melanoma cell lines. The subsequent analysis revealed six peptides (P1–P6) that were
recognized by HLA-A2-restricted TILs [115]. Subsequently, the method has been used to investigate
HLA-bound peptides in melanoma [116] and to isolate the first leukemia-specific immunogenic peptide
derived from the Bcr-Abl fusion protein [117] in order to develop peptide-based immunotherapy.
Acid stripping can be used to extract peptides from adherent and suspension cell lines. Moreover,
the approach is quite simple and cost effective. However, acid-treated cells are often damaged in
the process, releasing proteases that generate peptides from either abundant cell protein or from
cytoplasmic protein. Consequently, the peptides are often contaminated with non-HLA-restricted
peptides [11,118].
3.1.2. Soluble HLA Molecules
The use of soluble HLA molecules is based on cells engineered with the vector encoding the
desired soluble HLA complex. This approach requires the generation and isolation of stable transfected
cells to express the soluble HLA molecule. The latter lacks the transmembrane domain that is needed
for it to be secreted. Hence, the soluble HLA is released in the cellular medium that is collected and
immunopurified for the further characterization of peptides [11,119].
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Different approaches for generating the soluble HLA-I complex have been used over the years.
In 1986, McCluskey and co-workers developed a soluble HLA molecule by fusing the non-functional
transmembrane carboxyl terminal C2 domain of Q10b with the polymorphic amino-terminal N and
C1 domains of H-2Dd, thus generating a chimeric H2DD/Q10b molecule [120]. In the following years,
another group realized a soluble HLA as a fusion protein between the extracellular domain of H2Kb
and the immunoglobulin heavy chain polypeptide [121]. A third approach to generating soluble HLA
has been reported by Grumet et al. The authors removed the transmembrane and cytoplasmatic
regions from the B7 gene, creating soluble HLA-B07 (sHLA-B7) that in in vivo experiments suppressed
humoral alloimmunization [122].
Soluble HLA molecules have been extensively used in investigating the immunopeptidome
landscape in order to identify novel peptide candidates for therapeutic vaccines in the fields of cancer
immunotherapy [123,124] and infectious diseases [125–128]. The use of soluble HLA for peptide
isolation has been proposed as a valid alternative to immunoaffinity purification [119]. In some
cases, the yield of retrieved peptides has been reported as improved compared to immunoaffinity
purification [124]. Nevertheless, the approach is not feasible to study patient tumor samples or tissue
because it requires the generation of stable transfected cells.
3.1.3. Immunoaffinity Purification
Immunoaffinity purification relies on the direct isolation of HLA-I complexes from solubilized
samples that are subsequently applied to columns and previously coupled with monoclonal antibodies
that are able to bind the desired HLA-complex. The peptides are isolated from the HLA complex
through acid elution and purification. The sequence is resolved by tandem mass spectrometry (MS/MS)
analysis and validated in in vitro and in silico assays (e.g., motif clustering analysis) [11].
Briefly, the protocol starts with selecting the material to process; this material can be cells, tissue,
biopsies, or biological liquid (i.e., plasma) [129]. Cells are the simplest material to work with because
it is possible to expand them in culture and preserve the pellets by freezing them at −80 ◦C for
up to 6 months [11]. The amount is usually in the range of 5 × 107 and 1 × 109 cells [11]. Next,
the material is lysed using a lysis buffer that is a combination of a 0.5–2% solubilization reagent (e.g.,
Igepal, sodium deoxycholate, CHAPS), salts, and protease inhibitors [11,14,118]. The cell lysate is then
centrifugated and the supernatant applied to the columns coupled with a monoclonal antibody.
The choice of monoclonal antibodies varies depending on the experimental conditions according to
the investigated material and to the desired HLA complex. After the HLA complex binding, the columns
are washed extremely well to get rid of material that is not specifically bound, detergent that could
interfere with the downstream mass spectrometry analysis, and salts that could form crystal precipitates.
The final step is the elution of the peptides from the HLA complexes. This is achieved using an acid
solution with a pH of 3.0 (e.g., 10% acetic acid). Purification of the peptides is carried out using C18
columns or low-protein binding with a molecular weight cut-off (MWCO) spin filter. The fraction
containing the HLA peptides is then vacuum-dried to reduce the acetonitrile concentration and
analyzed by mass spectrometry to resolve the amino acid sequences [11,14].
An early attempt to isolate HLA-I antigens using immunoaffinity purification was reported by
Parham in the 1970s [130]. In this work, the author demonstrated the feasibility of isolating the HLA-A02
and HLA-B07 complexes’ antigens, starting from the crude membrane of the JY cell line. The sample
was applied to a series of columns, each one respectively coupled with the monoclonal antibodies
anti-HLA-A02, anti-HLA-B07, and anti-pan HLA-I. This first attempt paved the way to studying
the ligandome landscape using immunoaffinity purification. Immunoaffinity purification evolved
profoundly over the subsequent years and has been used to systemically analyze the HLA-restricted
peptides derived either from virus- or cancer-transformed cells, as shown in the work of Engelhard
and Hunt [131–136], Natheson [137], and Rammensee [138]. For instance, immunoaffinity purification
has been used to identify the peptides that are recognized by CTLs derived from patients, as shown
by Cox et al. Cox et al. isolated peptides from melanoma cells via immunoaffinity purification;
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nine peptides were found to be recognized by CTLs derived from different patients, showing the
feasibility of identifying candidates for peptide-based vaccines [132]. Immunoaffinity purification
has been used to investigate antigens in malignant and non-malignant samples in order to define a
pool of tumor-restricted peptides. This approach led to the successful identification of the peptides
which are exclusive to tumors that are able to activate pre-existing T cells in colorectal carcinoma
patients [138]. Interestingly, immunoaffinity purification can be used to identify spontaneous T cell
responses in malignancies with few described associated antigens; for example, in chronic lymphocytic
leukemia [139].
Immunoaffinity purification results in highly specific HLA peptides; however, the number
and quality of the retrieved sequences is strongly affected by the following circumstances. Firstly,
the material to be processed has to be provided in large amounts (5 × 107–1 × 109 cells), preventing
the analysis of small and often clinically relevant tissues (e.g., needle biopsies) [11,140]. Secondly,
the expression level of the HLA varies according to the samples, thus impacting the final number
of peptides. Moreover, specific anti-HLA antibodies are not always available or are not optimal for
binding. Finally, the use of spin filters has been associated with polymer contamination and peptide
loss [11].
3.2. Proteogenomics
Proteogenomics is a broad research area that combines knowledge from the proteomic and
genomic fields. Indeed, it combines the rapidly developing MS/MS approaches in proteomics with
the high-throughput sequencing methodologies of genomics. The aim of proteomics is to identify
and characterize (e.g., cellular localization, signaling pathway) the proteome of a given species.
From a technical point of view, this aim is achieved through the digestion of proteins to generate
peptides. Regarding the analysis of the immunopeptidome landscape, peptides are isolated from
HLA-I complexes according to one of the aforementioned methods (Section 3.1.1, Section 3.1.2,
and Section 3.1.3). The peptides are then resolved by MS/MS analysis, and the generated spectra
are searched against the theoretical spectra of all candidate peptides, as represented in conventional
reference databases (e.g., EntrezProtein, UniProtKB). These databases contain all the protein-coding
sequences in the genome. Mutations, products of novel coding proteins or of annotated non-coding
regions, and frameshifts cannot be identified because the spectra do not match any references in the
canonical database [141], hindering the identification of potential vaccine peptides such as neo-antigens.
Genomics examines the genome organization (e.g., gene–gene interactions) within a given
organism and mainly relies on sequencing approaches (whole genome sequencing, RNA sequencing)
and bioinformatic algorithms for the subsequent interpretation of data. The introduction of next-generation
sequencing (NGS) and the advancement of bioinformatics have revolutionized our approach to DNA
and RNA sequence analysis, paving the way for tailored therapeutic cancer treatment. With respect
to HLA-restricted tumor antigens, sequencing methods direct the identification of patient-specific
neoantigens in therapeutic settings, taking advantage of whole exome sequencing-based mutation
calling [94,142]. In 2017, Sahin et al. reported the first example of neo-epitope prediction, which was
applied to the development of a cancer vaccine for the treatment of 13 melanoma patients [143].
The authors identified nonsynonymous mutations by the comparative exome and RNA sequencing
(RNA-seq) of tumor biopsies and healthy blood cells. They then prioritized the neo-epitopes with
predicted high affinity binding to the autologous HLA and a high expression level of RNA. This led
the authors to develop an RNA vaccine encoding poly-neoepitopes for personalized melanoma
treatment [143]. Following a similar approach, Wu et al. created a vaccine to target personal neoantigens.
The authors used a whole exome sequencing of a patient’s tumor and normal cells to identify somatic
mutations and RNA sequencing in order to confirm the mutation expression. Peptide selection was
based on the predicted binding affinity to the autologous HLA, developing synthetic long peptides
containing up to 20 neoantigens per patient [144]. Even though knowledge of the genome and/or
the RNA expression level allows researchers to make inferences about the use of HLA-I peptides for
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a therapeutic cancer vaccine, the genomic approach by its very nature does not take into account
post-translational modifications such as methylation, phosphorylation, and glycosylation. These have
reportedly been involved in eliciting T cell immune responses and can be identified solely using
MS/MS approaches [145–147]. For instance, phosphorylated peptides, but not their unphosphorylated
homologous peptides, were recognized by CD8+T cells [146]. In addition, sequencing analysis lacks
authentic knowledge of the HLA presentation, as the complex pathway underlying the presentation
machinery cannot be completely deduced from the sequencing methodology and downstream
bioinformatic analysis.
In 2004, Church et al. for the first time combined the potential of proteomics with global genome
annotation, developing a new method for mapping the peptides detected in Mycoplasma pneumoniae.
The method was named “proteogenomic mapping” [148]. Thus, proteogenomics as a science was born
in 2004 in order to integrate genome annotation and proteomic application [141].
Applied to HLA ligandome analysis, proteogenomics addresses two main issues—the actual
presentation of HLA peptides in the genomic analysis and the need for patient- or sample-specific
mutation databases in order to search for spectra data [149]. The main rationale is the use of exome
sequencing mutation calling in order to identify mutations in tumor samples and RNA-seq to confirm
their expression. The sequencing data are then used to assemble tailored databases to investigate
the proteomic data in the form of MS/MS spectra which are derived from the immunopeptidome
analysis of the same samples. This approach has been successfully applied to the identification of
HLA-restricted tumor neoantigens [150–152].
Recently, Bassani–Sternberg and colleagues described a proteogenomic pipeline for the identification
of non-canonical peptides (long non-coding genes, UTRs, transposable elements, pseudogenes) from
the ligandome repertoire [153]. Using MS/MS, the authors compared the immunopeptidome landscape
of seven patient-derived melanoma cell lines and two pairs of lung cancer samples with matched
healthy tissues. Using the same sample, they performed exome sequencing mutation calling and RNA
sequencing analysis. The MS data were then compared against a personalized database built from
the translation of the transcripts acquired from the sequencing analysis. This approach identified
hundreds of non-canonical HLA peptides [153]. The combination of exome sequencing and MS/MS
was also used in Kalaora et al. to investigate immunogenic neoepitopes in human melanoma [154].
Proteogenomics is a promising method to shed light on the antigen landscape, especially to
identify neoantigens which are otherwise not detectable with conventional approaches. However,
the amount of samples required for proteomic analysis is still high, hampering the investigation of
small amounts of material (e.g., needle biopsies) [155].
4. Prediction of T Cell Epitopes
As mentioned, CTLs control the health of an organism, recognizing linear peptides which
are presented on the MHC or, in humans, the HLA molecule. This system allows T cells to scan
intracellularly processed proteins and consequently have an indication of the metabolic state of the
cells; for example, whether they are transformed (cancerous) or virally infected. Protein degradation
is mainly performed by the proteasome; however, the contribution of other proteases at this point
seems clear [156]. The cleaved peptides are then transported in the endoplasmic reticulum (ER) by an
ATP-binding complex called transporter-associated antigen processing (TAP). Other mechanisms of
peptide translocation into the ER are evident yet poorly understood [157]. In the ER, peptides bind
to the MHC molecule and are transported to the cell’s surface, where the complex (pMHC) will be
potentially recognized by the TCRs of CD8+ T cells (Figure 3).
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4.1. Prediction of Antigen Processing and Presentation
4.1.1. Proteasomal Cleavage Prediction
The proteasome is a multi-catalytic protease complex that is formed by different sub-units and
represents the cellular main center of the degradation of misfolded or un-needed proteins. The core of
the proteolytic machinery is the 20S complex that contains three catalytic sub-units (β1, β2, and β5)
that have specific catalytic activity: peptidyl-glutamyl-peptide-hydrolyzing activity (cleavage after
acidic amino acids), trypsin-like activity (cleavage after basic amino acids), and chymotrypsin-like
activity (cleavage after large, hydrophobic amino acids), respectively [158]. In the context of antigen
presentation, proteasomes have been experimentally shown to be involved in the production of the
C-termini of peptides [159,160].
Cells which are exposed to IFNγ substitute the constitutive β1, β2, and β5 with the homologs
LMP2 (β1i), MECL1 (β2i), and LMP7 (β5i) that are encoded in the same locus as the HLA molecules and
for this reason are historically associated with “immune”-related activity. This newly formed protease
complex is called immunoproteasome, and its catalytic activity is characterized by reduced cleavage
after acidic amino acid residues and increased cleavage after hydrophobic and basic residues [158].
Proteasomal cleavage is the first step in the antigen processing machinery; therefore, significant effort
has been made to develop models that are able to predict its activity.
Currently, the tool which is generally recognized as the best performing tool to predict both
proteasomal and immuno-proteasomal cleavage is NetChop 3.1 [161]. This is an updated version
of a previously developed artificial neural network (ANN) architecture [162]. Benchmarked with
other proteasome cleavage prediction tools, NetChop has been shown to be better at predicting MHCI
epitopes. It has been speculated that NetChop is better at predicting naturally processed epitopes
because it is trained with HLA ligand data, unlike other tools that have been trained with in vitro
proteasomal cleavage data only. This might have allowed the model to better generalize the different
contributions coming from additional proteases [156]. Interestingly, proteasomes can also generate
different kinds of epitopes by joining non-contiguous regions through a process called post-translational
peptide splicing [163,164]. However, bioinformatic tools which are able to predict this phenomenon
are currently lacking.
4.1.2. TAP Binding Prediction
The TAP complex is a heterodimer composed of two proteins, TAP1 and TAP2. It is an ATP-binding
transporter delegated to the transport of peptides from the cytosol into the ER. Here, the peptides
might be further processed by aminopeptidases or directly loaded onto the MHC and successively
transported through the cell’s surface. It has been shown that the TAP transporter prioritizes peptides
of certain lengths and carboxyl terminus residues commonly found to be HLA class I anchors,
with minor contributions (positive and negative) from residues in other positions. It has therefore been
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speculated that there is a coevolution of TAP with the MHC (despite its high polymorphism) [158].
Models to predict TAP’s transport efficiency with peptides of arbitrary length have been produced
over time [165,166], showing some improvement in epitope prediction efficiency. This approach has
never been very successful alone; however, it has found a discrete use in combination with methods
that will be discussed later.
Recently, it has been demonstrated that TAP-independent transport has a relevant role in CTL
epitope production [157,167]. However, the possible mechanisms and the weight that it has globally
on epitope presentation remain largely unknown [168].
4.1.3. Peptide–MHC Binding Prediction
HLA is considered the most polymorphic protein of the human genome (hyper-polymorphic
protein). The class I region, located on chromosome 6, encodes for genes that form HLA class I
molecules. Interestingly, just the HLA-A, -B, and -C gene polymorphisms account for the almost
17,000 different alleles which have been annotated so far [169]. Notably, despite the incredibly large
number of alleles, the HLA class I molecules can be clustered into nine groups called “supertypes” that
reflect close peptide-binding specificity [170]. However, each allele in a supertype has a unique and
specific peptide-binding preference. Therefore, the fact that a peptide can bind to a given allele does
not necessarily indicate that it can also bind to other alleles of the same supertype [171].
HLA Motif Deconvolution
Despite the constant increase in MS-eluted immune peptidome data [172–174], HLA peptide
deconvolution—the process of associating each ligand to its presenting HLA molecule(s)—is still a
critical task. The tool most commonly used to this end is GibbsCluster 2.0. It performs sequential
unsupervised alignments and clustering tasks of peptide sequencing based on Gibbs sampling.
The latest version can also handle variations in peptide length for the generation of a motif [175–177].
Interestingly, it has been shown that incorporating deconvoluted HLA peptidomics data can
improve the accuracy of HLA-binding prediction tools for those HLA alleles with still few ligands in
the existing databases [178]. This approach can be used to refine our understanding of peptide–HLA
interaction when considering peptides which are longer than nine amino acids (generally the most
common and studied length), as the motif can change slightly when longer ligands interact with
HLAs [178]. This technique has been shown to help increase the yield of immunopeptidome runs by
20–30% [179].
MHC-Binding Affinity Prediction
MHC alleles may differ because of different amino acid substitutions, most of which are found
within the binding site and are critical to determining peptide motif recognition [170]. One of the
most crucial steps in the antigen presentation pathway is the ability of the peptide to form a complex
with the HLA molecule, thus determining its probability of being presented. The ability to predict the
peptide affinity for the HLA is generally recognized as a key factor in the selection of T cell epitopes.
The first attempts to predict peptides’ MHC-binding affinity relied on motif search techniques, but
today, machine learning-based methods are preferred.
One of the most commonly used tools to predict MHC-binding affinity is NetMHC 4.0 [180],
a feed-forward ANN ensemble with a single hidden layer which has been trained with a set of
quantitative peptide-MHC class I affinity measurements from the Immune Epitope Database (IEDB)
of peptides of different lengths. Another ANN-based tool is MHCflurry [181]. This is an open
source package, and its architecture combines the use of locally connected and fully connected layers
which have been trained with both experimental affinity measurements and MS-eluted peptides for
allele-specific prediction.
Other methods are called pan-specific as they accept both peptide and HLA amino acid sequences
and are able predict the affinity of any peptide to any HLA-I.
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NetMHCpan is the most commonly used tool [182], and in its latest version (NetMHCpan 4.0) [183],
an increased prediction accuracy has been reached by adding MS-eluted peptide data into the
training set.
Interestingly, PSSMHCpan [184] is a pan-specific HLA-binding affinity method based on
allele-specific position-specific scoring matrices (PSSM) which are generated by multiple sequence
alignments of peptides binding to already characterized HLAs. When uncharacterized HLAs are
encountered, the algorithm uses the similarity to the nearest HLA sequence as a weight that affects the
binding score for the queried HLA.
In recent years, deep learning, a particular neural network architecture, has shown its power in
classification and regression tasks and has attracted increasing attention. Zhao et al. [185] developed a
convolutional neural network that uses different peptide properties, such as the order of the sequence,
the hydropathy index, polarity, and the length of peptide needed to perform the prediction, as these
are the key factors in determining the binding to the HLA molecule. Zeng and Gifford developed
a deep learning-based method that consists of a binding affinity prediction module and a peptide
embedding module [186]. The latter applies a deep language model to embed each peptide into
a vector representation. The concatenated output of the two models represents the input for a
fully connected neural network (NN). Zeng and Gifford also suggested a residual neural network
(PUFFIN) that quantifies the uncertainty in peptide–HLA affinity prediction or, in other words,
determines the confidence of the prediction [187]. Another recently developed pan-specific method
is ACME [188], which consists of a deep convolutional neural network (CNN) implemented with an
attention mechanism that returns interpretable patterns that facilitate the prediction. DeepHLApan is
a recurrent neural network (RNN)-based method that takes neoepitopes as inputs and considers both
the possibility of mutant peptide presentation and its potential immunogenicity [189].
Over time, sequence-based machine learning-driven methodologies have become increasingly
popular because of their predictive power. However, they give poor structural insights into the
dynamics of the interactions between the peptides and the HLA molecules. Modeling approaches
are suitable tools to tackle this problem, but their use has been hindered for many years because
of the high computational power required. In recent years, different tools have been developed for
this purpose, or existing tools have been implemented to enhance their performance. One such tool
is the web-server tool DockTope [190], currently hosted by IEDB (http://tools.iedb.org/docktope/).
DockTope is able to iteratively model pMHC-I complexes until the best conformation is found, but given
the small number of crystal structures of pMHC complexes that is available, the tool is only able to
model the conformations of two human (HLA-A*02:01 and HLA-B*27:05) and two murine (H-2-Db
and H-2-Kb) MHC-I allotypes. DINC [191] is another web-server tool based on the incremental
meta-docking approach that has high accuracy in predicting the geometry of peptides in a complex
with MHC molecules. GradDock [192] is a fast and accurate structure modeling algorithm for pMHC-I.
The docking simulator was designed to be unbiased toward any MHC-I molecules by generating the
initial unbound peptides in vacuo and successively inserting them into the desired MHC-I molecules.
Finally, APE-Gen [193] is a very fast and accurate modeling method that has the potential to be
useful because of its scalability (i.e., modeling thousands of pMHCs or non-canonical longer peptides)
and flexibility.
4.1.4. Combination of Different Predicting Tools
In order to better mimic all the processing and presentation steps that a naturally presented
epitope goes through, approaches that combine different single step predictors have been produced.
Tools such as NetCTL and NetCTLpan have shown that the combination strategy is more effective
than individual tools in predicting naturally presented epitopes [194,195]. NetMHCcons combines the
predictive power of three state-of-the-art peptide–MHC binding predictors and has been shown to
outperform individual tools [196]. The ultimate advantage of using a combination of the previously
described methods is that the number of candidate peptides to be tested is significantly reduced
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compared to predictions based on individual methods. Nevertheless, a comprehensive benchmarking
of all these tools has never been performed.
4.2. Prediction of Epitope Immunogenicity
At this point, it is important to note that the ability of a peptide to bind the HLA molecule and be
present on the cell’s surface does not imply its ability to engage a T cell and promote its activation.
There is a difference between naturally presented epitopes; some are able to elicit an immune response
(and, hence, are immunogenic) and some are not.
4.2.1. Peptide Stability Prediction
A peptide’s affinity to a specific HLA molecule is crucial for its presentation, yet it does not
give any indication about its possible recognition by a T cell. A step forward in this sense has been
taken by Jørgensen and Rasmussen, who respectively developed NetMHCstab and NetMHCstabpan,
which are ANN-based methods for predicting the stability of the pHLA complex [197,198]. They have
shown that the integration of peptide-HLA binding affinity predictors with pHLA stability prediction
significantly improves the identification of CTL epitopes. Moreover, assuming that longer lasting
epitope presentation increases the likelihood of T cell recognition, they show that pMHC stability
better correlates with immunogenicity than HLA binding affinity.
4.2.2. Inherent Peptide Immunogenicity
Immunogenicity is defined as the ability of a given antigen—in this case, a pHLA complex—to
elicit an immune response. There are different possible approaches to address this problem. One of
these considers immunogenicity as an inherent property of the peptide. The first attempts to predict
immunogenicity produced POPI (an SVM-based predictor) and POPSIK (an SVM-based method using
the weighted degree string kernel). These models explored the physicochemical properties derived
by the AA index [199] of the amino acid composing the peptides. Of the properties selected by the
models, four were hydrophobicity-related and two were residue volume-related [200,201].
Calis et al. produced a scoring model derived by summing the log enrichment scores of amino
acids found at non-anchor positions weighted by the importance of that position for immunogenic
peptides compared to non-immunogenic peptides [202]. In the same year, Saethang et al. developed
a method for predicting T cell reactivity based on peptide encoding using a combination of amino
acid pairwise contact potentials (AAPPs) and quantum topological molecular similarity (QTMS)
descriptors [203]. More recently, Zhang et al. attempted to predict immunogenic peptides based on
their sequences. They analyzed the relationships between different features vis-à-vis immunogenicity
and selected the optimal feature subset using a genetic algorithm [204].
Some interesting attempts to produce an integrated method are NepTepi [205], which comprises
several of the HLA-binding affinity methods described above, the pMHC complex stability
NetMHCStab, and the immunogenicity model produced by Calis et al.
Despite these efforts, however, immunogenicity remains a feature that is far more difficult to
model and predict than mere MHC-binding affinity. On one hand, this might be a problem that is
just due to the limited amount of data. On the other hand, it might reflect a more complex biological
scenario; for example, genetic background (HLA haplotype), central tolerance, and TCR repertoire.
4.2.3. Interaction with T Cells
All existing approaches to predicting epitope presentation do not consider whether that epitope is
going to be recognized by a CTL. Previously, it has been shown how immunogenicity can, to a certain
extent, be predicted by analyzing the sequence-specific features of HLA-bound peptides. Nevertheless,
the results have been poor, as only one side of the immunological synapsis has been considered.
Recently, the more widely used multimers-based technology [206] and the development of single cell
TCR sequencing have, to a certain extent, filled the gap between TCR sequences and their recognition
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specificity, thus increasing the amount of experimental data available. This has given rise to different
databases, such as McPAS-TCR [207], VDJdb [208,209], IEDB [210], STCRDab [211], and ATLAS [212].
An interesting work that brings peptide–TCR recognition to the same side is that of Gielis et al.,
who identified epitope-specific TCR sequences using a random forest algorithm [213]. However, it can
only predict TCR sequences based on the peptides present in the training database.
Oghishi and Yotsuyanagi et al. abandoned the long-standing idea that the TCR repertoire is highly
stochastic and individualized, showing that epitope recognition by T cells is to some extent predictable.
The authors used a method to approximate the molecular scanning process of the presented peptides
by the TCR repertoire, reducing the problem to an alignment-based approach [214].
Another valuable strategy for the future is to undertake structural modeling of the interaction
between the pMHC and the TCR. With this concept in mind, Jensen et al. developed the TCRp-MHC
model [215], a tool that accepts as input the amino acid sequence of both the peptide and the TCR of
interest (alpha and beta chains). The tool automatically identifies the best structural templates and
generates a structural model of the target using comparative modeling.
TCRp-MHC models the pMHC and the TCR separately using MODELLER and LYRA [216],
respectively, after which they are assembled in an additional modeling step to form the full TCR-pMHC
complex. Interestingly, the structural models generated by the tool have high quality and are generated
within a computational time of only 2 min.
5. Conclusions
The advancements in antigen discovery have paved the way for a deeper understating of the
complex interaction between peptides and the HLA-I complex on one side and between HLA-I-restricted
peptides and CD8+ T cells on the other. This knowledge is the key to developing efficient strategies
for cancer therapeutic vaccines. To reach a better outcome and to exploit the overall potential of the
antigen discovery approaches, several challenges must be addressed. One is that the HLA in vitro
methods suffer from a lack of lab-to-lab reproducibility, hampering the impartial comparison of the
generated HLA-I ligand datasets. This issue demands the urgent standardization of the protocol
used for the isolation of peptides. Moreover, the community would generally benefit from technical
advancements that allow the analysis of small amounts of tumor material (e.g., needle biopsies).
In addition, the availability of open access datasets encourages collaboration among the different labs
involved in antigen discovery. This will ultimately facilitate reliable progress in the field of cancer
immunotherapeutic treatment. Regarding the in silico approaches, the production of an increasing
amount of experimental data surely facilitates the generation of models to predict given phenomena.
However, the presence of sparse databases which sometimes contain redundant data makes the
collection, processing, and analysis of data tedious and difficult. The continuous production of new
prediction algorithms is a great achievement; however, benchmarking these tools is an increasingly
difficult task because of the limited amount of data in the respective training sets. Moreover, the use of
too many different tools and pipelines creates confusion about the best practices to follow.
We believe that the combination of in vitro methods and in silico approaches is the key to tackling
the complex interaction between tumor antigens and the T cell immune response. This necessary
interdisciplinary expertise would expand our knowledge and ultimately benefit cancer patients.
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